| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_518bd553491022322a28c6cf6aa898f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38378daf24990a4bcf7fb37c1a42edd0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2005-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8183d3ed9a686ef045262e9b1e49f853 |
| publicationDate |
2005-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005094265-A2 |
| titleOfInvention |
Self assembling activation agents targeted using active drug release |
| abstract |
In a method for therapeutic treatment of humans and other mammals, the therapeutic composition includes a fusogenic encapsulation vesicle and an activation agent such as an organic nanotube or α-DL peptide enclosed in the encapsulation vesicle. The activation agent is maintained in an inactivated form and becomes activated by an activation condition. |
| priorityDate |
2004-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |